Scientific abstract presentations at EHA2024
ASH2023: New research on patient outcomes presented
Researchers validate novel risk profile for childhood ALL using ...
New HARMONY Delphi Survey for #ALL Core Outcome Set open
ALL-5: Exploring the prognostic significance of minimal residual ...
ALL-4: Harnessing the Power of Big Data to Predict Outcomes
ALL-3: Exploring treatment patterns and outcomes in older adult ...
Use of Big Data to improve outcomes for patients with Acute
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands